- $148.58m
- $194.70m
- $149.16m
Neuronetics Inc expected to post a loss of 39 cents a share - Earnings Preview
Brief: Neuronetics Announces Continued Momentum For Expanded Health Insurance Coverage For Tms Therapy
Brief: Neuronetics Inc - Holds Balance Of Less Than $1 Million In Cash With Silicon Valley Bank
U.S. RESEARCH ROUNDUP-Tesla, Oracle, Caredx
Neuronetics falls after dour 2023 revenue forecast
Neuronetics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Neuronetics Reports Record Fourth Quarter And Record Full Year 2022 Financial And Operating Results
Neuronetics Inc expected to post a loss of 38 cents a share - Earnings Preview
Brief: Neuronetics Announces Tms Coverage Criteria Changes For Over 23 Million Covered Lives
Neuronetics rises on supply deal with Greenbrook
Brief: Neuronetics And Greenbrook TMS Announce Six Year Exclusive Partnership
Brief: Neuronetics Announces Data Confirming Efficacy In Treating Anxious Depression With NeuroStar Advanced Therapy For Mental Health
Brief: Neuronetics Settles Litigation Against Brainsway
Brief: Neuronetics Says Preliminary Unaudited Total Revenue For Q4 Of 2022 Is About $18.0 Million
Neuronetics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Neuronetics Reports Third Quarter 2022 Results
Neuronetics Inc expected to post a loss of 42 cents a share - Earnings Preview
Brief: Neuronetics Announces 510(K) Clearance Of D-Tect MT Accessory For Neurostar Advanced Therapy For Mental Health
Brief: Neuronetics Inc - Bruce J. Shook Notified Board Of His Decision To Resign From Board Effective As Of October 31, 2022